Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/23/2024 | $157.00 → $182.00 | Neutral → Outperform | Robert W. Baird | |
| 8/28/2024 | $165.00 | In-line | Evercore ISI | |
| 7/10/2024 | $145.00 → $165.00 | Neutral → Buy | Citigroup | |
| 2/26/2024 | $135.00 | Market Perform | Leerink Partners | |
| 2/7/2024 | $140.00 → $155.00 | Hold → Buy | Jefferies | |
| 1/3/2024 | $145.00 | Equal Weight | Barclays | |
| 12/12/2023 | $140.00 → $160.00 | Neutral → Buy | BofA Securities | |
| 6/29/2023 | Neutral | Piper Sandler |
The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits.
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Quest Diagnostics (NYSE:DGX) in the last three months. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 4 0 0 Last 30D 0 0 1 0 0 1M Ago 1 0 2 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $157.0, a high estimate of $165.00, and a low estimate of $153.00. Marking an increase of 5.37%, the
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $153 to $154.
BASKING RIDGE, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced it has entered into a sponsored research agreement with the University of Cincinnati to investigate Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab (a VEGF inhibitor) in a preclinical animal model for the treatment of endometriosis. Bevacizumab has previously demonstrated efficacy in treating endometriosis; however, the required dosage levels are associated with systemic side effects, limiting
Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh
BASKING RIDGE, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that Erkki Ruoslahti, M.D., Ph.D., has decided to retire from its Board of Directors effective today, July 11, 2023. Dr. Ruoslahti will remain associated with the Company, however, in a scientific advisory position. Dr. Ruoslahti cites the arduous requirements of international travel (he currently resides in Sweden) as well as his confidence in both the progress made with the Company's lead asset, LSTA1, and the
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
10-Q - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)
Robert W. Baird upgraded Quest Diagnostics from Neutral to Outperform and set a new price target of $182.00 from $157.00 previously
Evercore ISI resumed coverage of Quest Diagnostics with a rating of In-line and set a new price target of $165.00
Citigroup upgraded Quest Diagnostics from Neutral to Buy and set a new price target of $165.00 from $145.00 previously
SECAUCUS, N.J., Nov. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on January 29, 2025 to shareholders of record of Quest Diagnostics common stock on January 14, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to t
Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the third quarter ended September 30, 2024. "We are pleased to share the progress made in the third quarter of 2024, highlighted by the advancement of our robust development portfolio centered ar
BASKING RIDGE, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To
SECAUCUS, N.J., Nov. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on January 29, 2025 to shareholders of record of Quest Diagnostics common stock on January 14, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to t
Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the third quarter ended September 30, 2024. "We are pleased to share the progress made in the third quarter of 2024, highlighted by the advancement of our robust development portfolio centered ar
BASKING RIDGE, N.J. and HELSINKI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Valo Therapeutics Oy ("ValoTx"), a private company developing novel, adaptable immunotherapies for the treatment of cancer, are pleased to announce a preclinical research collaboration to investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's innovative platform technology, PeptiCRAd, and a checkpoint inhibitor in a melanoma mouse model. Under the agreement, ValoTx will be conducting the researc
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)